Malmö, Sweden

Ab Ferrosan


USPTO Granted Patents = 18

Forward Citations = 351

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Sven E Hernestam (9 out of 9 patents)

silverMedal Anders K Bjork (8 out of 8 patents)

bronzeMedal Aina L Abramo (6 out of 11 patents)

4.  Erik G Christensson (5 out of 10 patents)

5.  Nils A Nilsson (4 out of 4 patents)

6.  Bengt Erik Kjellberg (4 out of 4 patents)

7.  Ake R Lindahl (3 out of 4 patents)

8.  Lars-Olof Willard (3 out of 3 patents)

9.  Knut G Olsson (3 out of 10 patents)

10.  Stig A Erlandsson (3 out of 3 patents)

11.  Willard Lars-Olof (1 out of 1 patent)

12.  Aina Lisbeth Abramo (1 out of 1 patent)

13.  Curt Harry Nordvi (1 out of 1 patent)

14.  Sven Eric Hernestam (1 out of 1 patent)

15.  Bengt Eric Kjellberg (1 out of 1 patent)


18 patents:

Company Overview
Ab Ferrosan, headquartered in Malmö, Sweden, specializes in the development and manufacturing of advanced medical devices and solutions. The company focuses on innovative technologies in the healthcare sector, particularly in areas such as surgical instruments and wound care products. With a commitment to enhancing patient outcomes, Ab Ferrosan leverages its expertise to create reliable and effective solutions that meet the evolving needs of healthcare professionals and patients alike.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

18 Patents

#14 in Malmö

#365 in Sweden

#34,217 in the World

Malmö, SE
Malmö, Sweden
Forward Citations = 351

20 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ab Ferrosan. Retrieved from https://idiyas.com/company/ab-ferrosan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…